Bookmark and Share
BioAssay: AID 765048

Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity at 10 uM

It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARalpha) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARgamma is not, and the effect of hPPARdelta is unknown. Here, we show that hPPARdelta-selective antagonists effectively inhibit HCV RNA replication. We describe the design, synthesis and pharmacological more ..
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Inactive(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 765048
Data Source: ChEMBL (976990)
Depositor Category: Literature, Extracted
BioAssay Version:
Deposit Date: 2014-05-03
Modify Date: 2014-08-24

Data Table ( Complete ):           View All Data
Target
Sequence: RecName: Full=Peroxisome proliferator-activated receptor delta; Short=PPAR-delta; AltName: Full=NUCI; AltName: Full=Nuclear hormone receptor 1; Short=NUC1; AltName: Full=Nuclear receptor subfamily 1 group C member 2; AltName: Full=Peroxisome proliferator-activated receptor beta; Short=PPAR-beta
Description ..   
Protein Family: The ligand binding domain of peroxisome proliferator-activated receptors
Comment ..   

Gene:PPARD     Related Protein 3D Structures     More BioActivity Data..
Tested Compound:
Description:
Title: Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.

Abstract: It has been reported that ligand-mediated transcription factor peroxisome proliferator-activated receptor alpha (hPPARalpha) is involved in hepatitis C virus (HCV) RNA replication, whereas hPPARgamma is not, and the effect of hPPARdelta is unknown. Here, we show that hPPARdelta-selective antagonists effectively inhibit HCV RNA replication. We describe the design, synthesis and pharmacological evaluation of a series of biphenyl-4-carboxylic acid-type hPPARdelta antagonists, including previously reported compounds, as candidate anti-HCV agents. A representative compound (4c) dose-dependently inhibited HCV RNA replication (EC50 0.22 muM), while exhibiting relatively weak cytotoxicity to the host cells (CC50 2.5 muM). It also showed an additive and dose-dependent effect on the inhibition of HCV RNA replication by pegylated interferon alpha (Peg-IFNalpha) alone and by both Peg-IFNalpha and ribavirin (currently the clinical treatment of choice for HCV infection). Thus, combination of a hPPARdelta antagonist with current therapy may improve the efficacy of treatment for HCV infection.
(PMID: 23891183)
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
Assay Type: Binding
Target Type: Target is a single protein chain
Assay Data Source: Scientific Literature
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Inhibition activity commentInhibition activity commentString
2Inhibition standard flagInhibition standard flagInteger
3Inhibition qualifierInhibition qualifierString
4Inhibition published valueInhibition published valueFloat
5Inhibition standard valueInhibition standard valueFloat

Data Table (Concise)
Data Table ( Complete ):     View All Data
PageFrom: